Background
Prior studies have found an apparent paradox: the acute phase outcomes in smokers after acute myocardial infarction (MI) are superior to those of nonsmokers. Further, smoking is reported to have impact on the metabolism of clopidogrel. This study aimed to examine whether this paradoxical finding exists in patients who underwent drug-eluting stent (DES) and were treated with clopidogrel.
Methods
From April 2003 to June 2010, 1424 consecutive patients with acute MI who underwent primary or rescue percutaneous coronary intervention (PCI) with DES and clopidogrel were enrolled. They were divided into three groups: current smokers ( n =486), previous smokers ( n =349) and nonsmokers ( n =589). The primary endpoint was a composite of 30-day, all-cause death, nonfatal MI or definite stent thrombosis.
Methods
From April 2003 to June 2010, 1424 consecutive patients with acute MI who underwent primary or rescue percutaneous coronary intervention (PCI) with DES and clopidogrel were enrolled. They were divided into three groups: current smokers ( n =486), previous smokers ( n =349) and nonsmokers ( n =589). The primary endpoint was a composite of 30-day, all-cause death, nonfatal MI or definite stent thrombosis.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
